Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study-Reference-Cited by-同舟云学术

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study

Published:2024-06 Issue: Volume:72 Page:102622
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Jin Zhi-Cheng,Chen Jian-Jian,Zhu Xiao-Li,Duan Xu-Hua,Xin Yu-Jing,Zhong Bin-Yan,Chen Jin-Zhang,Tie Jun,Zhu Kang-Shun,Zhang Lan,Huang Ming,Piao Ming-Jian,Li Xiao,Shi Hai-Bin,Liu Rui-Bao,Xu Ai-Bing,Ji Fanpu^ORCID,Wu Jian-Bing,Shao Guo-Liang,Li Hai-Liang,Huang Ming-Sheng,Peng Zhi-Yi,Ji Jian-Song,Yuan Chun-Wang,Liu Xiu-Feng,Hu Zhou-Chao,Yang Wei-Zhu,Yin Guo-Wen,Huang Jin-Hua,Ge Nai-Jian,Qi Xiaolong,Zhao Yang^ORCID,Zhou Jia-Wei,Xu Guo-Hui,Tu Qiang,Lin Hai-Lan,Zhang Yao-Jun,Jiang Hua,Shao Hai-Bo,Su Yong-Jie,Chen Ting-Song,Shi Bao-Qi,Zhou Xiang,Zhao Hai-Tao^ORCID,Zhu Hai-Dong,Ren Zheng-Gang,Teng Gao-Jun^ORCID,Jin Zhi-Cheng,Chen Jian-Jian,Zhu Xiao-Li,Duan Xu-Hua,Xin Yu-Jing,Zhong Bin-Yan,Chen Jin-Zhang,Tie Jun,Zhu Kang-Shun,Zhang Lan,Huang Ming,Piao Ming-Jian,Li Xiao,Shi Hai-Bin,Liu Rui-Bao,Xu Ai-Bing,Ji Fan-Pu,Wu Jian-Bing,Shao Guo-Liang,Li Hai-Liang,Huang Ming-Sheng,Peng Zhi-Yi,Ji Jian-Song,Yuan Chun-Wang,Liu Xiu-Feng,Hu Zhou-Chao,Yang Wei-Zhu,Yin Guo-Wen,Huang Jin-Hua,Ge Nai-Jian,Qi Xiao-Long,Zhao Yang,Zhou Jia-Wei,Xu Guo-Hui,Tu Qiang,Lin Hai-Lan,Zhang Yao-Jun,Jiang Hua,Shao Hai-Bo,Su Yong-Jie,Chen Ting-Song,Shi Bao-Qi,Xing Wen-Ge,Gu Shan-Zhi,Wang Wei-Dong,Wang Song,Wen Shu-Wei,Lv Wei-Fu,Zhu Xu,Mu Wei,Ren Wei-Xin,Lu Zai-Ming,Fan Yong,Li Jia-Ping,Zhao Wei,Zheng Chuan-Sheng,Zhao Xu-Ya,Zhao Hui,Xu Jian,Hu Wen-Hao,Lei Yan-Ming,Wu Qing-Hua,Niu Huan-Zhang,Li Jia-Rui,Han Jian-Jun,Feng Dui-Ping,Cai Zheng,Li Qing-Dong,Dai Zhen-Yu,Shi Rong-Shu,Chen Yong,Wang Wen-Jun,Yin Li-Nan,Zhou Xiang,Zhao Hai-Tao,Zhu Hai-Dong,Ren Zheng-Gang,Teng Gao-Jun

Publisher

Elsevier BV

Reference36 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Global burden of primary liver cancer in 2020 and predictions to 2040;Rumgay;J Hepatol,2022

3. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update;Reig;J Hepatol,2022

4. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study;Park;Liver Int,2015

5. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma;Llovet;Nat Rev Gastroenterol Hepatol,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma;Molecular Cancer;2024-09-06

2. Systematic treatment in unresectable hepatocellular carcinoma: The most concerns;iLIVER;2024-09

3. Advancements in second-line treatment research for hepatocellular carcinoma;Clinical and Translational Oncology;2024-08-20

4. Immune-targeted therapy with transarterial chemo(embolization) for unresectable HCC: a systematic review and meta-analysis;Frontiers in Immunology;2024-08-02

5. Clinical benefits of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors for unresectable hepatocellular carcinoma;World Journal of Gastrointestinal Oncology;2024-07-15